

AMENDMENTS TO THE CLAIMS

1. (Withdrawn, Currently Amended) A method for inducing a cytotoxic T cell (hereinafter, referred to as "CTL") comprising bringing peripheral lymphocyte cells into contact with a fragment of a protein, wherein said protein comprises:

a fragment of a protein, said protein comprising:

(i) the amino acid sequence shown in SEQ ID NO: 2; or

(ii) an amino acid sequence having at least 80% sequence identity to SEQ ID

NO: 2

wherein the amino acid residue at position 2 of said ~~peptide~~-fragment is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and

wherein said ~~peptide~~fragment can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to HLA-A24 or HLA-B55 antigen.

2. (Currently Amended) A peptide which is 8-14 amino acids long, and is:

(a) a ~~partial peptide~~-fragment of a protein, wherein the protein consists of

(i) the amino acid sequence shown in SEQ ID NO: 2; or

(ii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2;

wherein the amino acid residue at position 2 of said ~~peptide~~-fragment is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine,

isoleucine, tryptophan, or methionine, and whereinsaid ~~peptide~~-fragment can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.

3. (Cancelled)

4. (Currently Amended) The ~~peptide~~-fragment of claim 2, which comprises an amino acid sequence shown in any one of SEQ ID NO: 6 - 46.

5. (Cancelled)

6. (Currently Amended) An epitope peptide comprising a ~~peptide~~-fragment of claim 2.

7. (Currently Amended) An inducer of CTL comprising a ~~peptide~~fragment of claim 2 as an active ingredient.

8.-11. (Cancelled)

12. (Withdrawn, Currently Amended) A method for producing an antigen-presenting cell comprising the step of bringing a cell having antigen-presenting ability into contact with

(a) a fragment of a protein, said protein comprising:

(i) the amino acid sequence shown in SEQ ID NO: 2; or

(ii) an amino acid sequence having at least 80% sequence identity to SEQ ID

NO: 2

wherein the amino acid residue at position 2 of said ~~peptide~~-fragment is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and wherein said ~~peptide~~-fragment can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.

13. (Cancelled)

14. (Withdrawn, Currently amended) A method for inducing a CTL comprising the step of bringing peripheral lymphocyte cells into contact with

(a) a fragment of a protein said protein comprising

(i) the amino acid sequence shown in SEQ ID NO: 2; or

(ii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

wherein the amino acid residue at position 2 of said ~~peptide~~ fragment is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and wherein said ~~peptide~~ fragment can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.

15.-18.(Cancelled)

19. (Currently Amended) A tumor marker comprising a ~~peptide~~ fragment as set forth in claim 2.

20. (Original) The tumor marker of claim 19, which comprises at least 8 contiguous amino acids in the amino acid sequence shown in SEQ ID NO: 2.

21.- 24. (Cancelled)

25. (Previously Presented) The tumor marker of claim 19, wherein the tumor is sarcoma or renal cancer.

26. (Previously Presented) A diagnostic agent for tumor comprising a tumor marker of claim 19.

27. (Cancelled)